Status:

COMPLETED

Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine

Lead Sponsor:

Portland VA Medical Center

Collaborating Sponsors:

GlaxoSmithKline

Schering-Plough

Conditions:

Major Depression

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Objectives: 1. To determine whether paroxetine can prevent major depression in patients with hepatitis C (HCV) who are receiving pegylated-interferon (Peg-IFN). 2. To determine whether paroxetine can...

Eligibility Criteria

Inclusion

  • 18 or older
  • diagnosis of hepatitis C
  • agree to participate in the study with written informed consent
  • plan to undergo treatment with Peg-IFN + Ribavirin
  • compensated liver disease (hemoglobin value \> 12 gm/dL for females or \> 13 gm/dL for males, WBC \> 3000/mm3, platelets \> 70,000/mm3, albumin \> 3.0 g/dL or within 20% of LLN, Serum creatinine \< 1.4 mg/dL, thyroid stimulating hormone within normal limits
  • confirmation from female patients that adequate contraception is being practiced during treatment period and for 6 months after discontinuation of therapy
  • confirmation from male patients that acceptable contraception is being practiced

Exclusion

  • hypersensitivity to IFN, RBV, or paroxetine
  • chronic liver disease other than chronic HCV
  • hemolytic anemia from any cause including hemoglobinopathies
  • evidence of advance liver disease
  • any preexisting medical condition that could interfere with participation in the protocol
  • evidence of cardiac ischemia, a significant unstable cardiac arrhythmia, heart failure, recent coronary artery surgery, uncontrolled HTN, unstable angina, or MI within past 12 months
  • clinically significant retinal abnormalities
  • substance abuse (must have abstained from abusing substance for at least 6 months)
  • diagnosis of major depression in the past 6 weeks
  • currently receiving full therapeutic dose of antidepressant medications
  • diagnosis of bipolar disorder
  • active psychotic condition
  • active delirium
  • pregnant female patients, men whose sexual partner is currently pregnant, and men and women who are not practicing adequate contraception
  • female patients who are actively breast feeding
  • patients with a known history of non-compliance with medical treatment

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00357045

Last Update

July 27 2006

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.